Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively
impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-…

Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD),
including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …

Background— In animal models, brief periods of ischemia performed just at the time of
reperfusion can reduce infarct size, a phenomenon called postconditioning. In this prospective, …

Background Tuberous sclerosis complex is highly variable in clinical presentation and
findings. Disease manifestations continue to develop over the lifetime of an affected individual. …